The development of immunotherapy (namely, checkpoint inhibitors targeting the programmed death protein-1 (PD-1)/programmed death legand-1 (PDL-1) axis, as well as targeted inhibitors of the BRAF/MEK signaling cascade in melanoma, and the hedgehog signaling pathway in basal cell carcinoma (BCC). These immune-based and targeted therapies have dramatically changed the treatment options for locally advanced and metastatic melanoma, Merkel's cell carcinoma, cutaneous squamous cell carcinoma (cSCC), and BCC. In this article, we will briefly review the currently approved targeted and immunotherapy-based treatments for locally advanced and metastatic melanoma, Merkel's cell carcinoma, and cSCC and discuss various combinations of approved therapies, as well as emerging therapeutic candidates that are currently in clinical trials, including novel checkpoint inhibitors in development, intratumoral oncolytic agents (viral and nonviral), and various immune-based therapies such as toll-like receptor (TLR) agonists, adoptive T-cell therapy, T-cell costimulation, and innate immune cell therapy. For advanced BCC, we will discuss trials investigating the currently approved smoothened (SMO) inhibitors for neoadjuvant use, emerging SMO inhibitors in development, topical SMO inhibitors, alternative targets in the hedgehog signaling pathway, and the use of anti-PD-1 agents for advanced BCC both alone and in combination with SMO inhibitors.
Melanoma

Currently Approved BRAF and MEK Inhibitors
Vemurafenib is a small molecule inhibitor of the BRAF serine/threonine protein kinase that is found to be mutated in 40 to 60% of cutaneous melanomas (BRAF V600E/V600K) and was approved in 2011 for unresectable and metastatic melanoma harboring BRAF driver mutations.1 Dabrafenib is another BRAF inhibitor approved shortly after in 2013 for the treatment of late-stage BRAF-mutant melanoma.2 Development of resistance and rapid progression of disease has been observed with BRAF monotherapy due to compensatory MEK1/MEK 2 upregulation, leading to the approval of concurrent MEK inhibitors such as trametinib, cobimetinib, and binimetanib for use in combination with BRAF inhibitors.3–5 Currently approved combinations include dabrafenib/trametinib, vemurafenib/cobimetinib, and encorafenib/binimetanib.5

Currently Approved Immune Checkpoint Inhibitors
Ipilimumab is a monoclonal antibody directed against the cytotoxic T-lymphocyte associated protein-4 (CTLA-4) T-cell receptor (TCR), and was approved in 2015 for adjuvant therapy of stage-III melanoma.6 CTLA-4 is constitutively expressed on regulatory T-cells, as well as conventional T-cells after activation, and via interaction with B71/2 on antigen presenting cells leads to a downregulation of the immune response allowing tumor proliferation.7 The phase-III EORTC (European Organisation for Research and Treatment of Cancer) trial of ipilimumab 10 mg/kg compared with placebo leading to its approval showed significant improvement in recurrence-free survival (RFS) of 40.8% in the ipilimumab group versus 30.3% for placebo at the most recent 5-year follow-up; however, there was a high incidence (41.6%) of immune-related grade-3 and -4 events.8 More recent trials have evaluated a lower-dose regimen of 3 mg/kg, showing a decreased rate of grade 3 or higher toxicity (36.4% vs. 57%) and no difference in RFS at 3-year follow up.9 However, with the introduction of immune checkpoint inhibitors targeting the PD-1 axis associated with improved efficacy and lower toxicity, adjuvant ipilimumab has fallen out of favor.5

PD-1 (also known as CD279) is a transmembrane protein receptor predominantly expressed on memory T cells, as well as B cells, monocytes, natural killer (NK) and dendritic cells that has an important role in regulating the immune response and maintaining self-tolerance through apoptosis of antigen-specific T-cells and upregulation of regulatory T-cells when activated by binding to its ligands PDL-1 (B7-H1) and PDL-2 (B7-DC).10 PDL-2 is primarily expressed on antigen-presenting cells (APCs), dendritic cells, and macrophages.10 PD-1 is expressed on multiple cell types including antigen-presenting cells, dendritic cells, B cells, monocytes, epithelial cells, as well as multiple types of cancer cells, including melanoma, lung, renal, and ovarian carcinomas, thus contributing to the ability of tumor cells in these immunologically active cancers to evade the immune system via activation of the PD-1/PDL-1 axis.11 Pembrolizumab and nivolumab are monoclonal antibodies against PD-1, and were approved in 2014 for unresectable or metastatic melanoma.12 Nivolumab was also approved in combination with ipilimumab for unresectable BRAF-wild-type melanoma in 2015, and approval of anti-PD-1 agents as adjuvant treatment of stage-III melanoma following complete resection was granted for nivolumab in 2017 and pembrolizumab in 2019.

There are currently three commercially available PDL-1 inhibitors on the market, all of which are currently in clinical trials for melanoma (as detailed in below sections): atezolizumab, durvalumab, and avelumab.12 Atezolizumab was approved in 2016 for advanced urothelial carcinoma, and in 2019 for both advanced non–small-cell lung cancer (NSCLC), as well as advanced triple-negative breast carcinoma expressing PDL-1 (as demonstrated by the PD-L1 IHC22C3 pharmDx assay) in combination with paclitaxel. Durvalumab was approved in 2017 for advanced and metastatic urothelial carcinoma, and avelumab was approved in 2017 for metastatic MCC.

Clinical Trials of Anti-PDL-1 Agents as Monotherapy in Melanoma
Avelumab is currently in phase I (JAVELIN solid tumor trial, NCT01772004) for unresectable stage-IIIC/IV cutaneous and ocular melanoma that had progressed after at least one prior therapy for metastatic disease, and phase 1B results were reported in early 2019.13 The overall response rate was 21.6% (7.8% of patients with complete response and 13.8% with a partial response). The mean progression-free survival (PFS) was 3.1 months, and mean overall survival (OS) time was 17.2 months. No grade-4 treatment-related adverse events (TRAEs) or deaths occurred, and the rate of grade-3 TRAEs was 7.8%.13 Atezolizumab is slated to begin a phase-I trial (not yet recruiting) as a neoadjuvant agent prior to surgery for resectable stage IB–IIC melanoma meeting criteria for a sentinel lymph node biopsy (SLNB; NCT04020809).

Combination and Sequential Trials with Immunotherapy and Targeted Therapy
For patients with unresectable or metastatic BRAF-positive melanoma, the current therapeutic options include targeted therapies (BRAF/MEK inhibitor combinations), as well as anti-PD-1 immunotherapies. While the addition of MEK inhibitors improved the durability of clinical responses to BRAF inhibition, development of resistance remains an issue and the response durations achieved with targeted therapy combinations are shorter than those achieved with systemic immunotherapeutic agents.14 The potential utility of combination trials is being investigated, as targeted agents induce higher initial response rates but lack durability, while the clinical response to PD-1 immunotherapy is often slower at onset but more durable.15 In addition, preclinical studies have demonstrated increased CD8+ T lymphocyte infiltration in the tumor microenvironment and synergetic antitumor effects with a combination of BRAF/MEK inhibition and anti-PD-1 agents.16 As a result, many of the current clinical trials for unresectable BRAF-mutant melanoma are examining various combinations of PD-1 or PDL-1 inhibitors with one or more targeted (BRAF/MEK) therapies.17 The initial study to evaluate a combination of a BRAF inhibitor (vemurafenib) with immunotherapy (ipilimumab) in 2013 was halted in phase I due to development of severe
liver toxicity (NCT01400051). Owing in part to the toxicity observed with ipilimumab in combination with BRAF inhibitors, newer combination studies have focused on PD-1/PDL-1 inhibitors. Phase-Ib results were reported from a combination trial of atezolizumab (anti-PDL-1) and vemurafenib in 2015, demonstrating an overall response rate of 76% (58% partial response and 17% complete response) with median duration of response 20.9 months and no severe adverse events observed (NCT01646442).

Multiple recent clinical trials are examining a triple combination regimen with anti PD-1/PDL-1 agent, BRAF inhibitor, and a MEK inhibitor. The anti-PD-1 durvalumab was evaluated in combination with dabrafenib and trametinib in a phase-I trial of patients with advanced BRAF-mutant melanoma that completed in 2018 (NCT02027961). The overall response rate was 69%, and dose-limiting toxicity (reversible grade 3 thrombocytopenia) was observed in one out of 26 patients on the triple therapy regimen. Phase-I data were reported in 2017 from the KEYNOTE-022 study of pembrolizumab, dabrafenib, and trametinib in 15 patients with BRAF-mutant stage III/IV melanoma. The overall response rate was 67%, and dose-limiting toxicities (grades 3 and 4 increase in aminotransferases and grade-4 neutropenia) were reported in 3 of 15 patients and resolved after drug discontinuation. Phase II of KEYNOTE-022 compared dabrafenib, trametinib, and pembrolizumab to dabrafenib and trametinib in a total of 120 patients with BRAF-positive melanoma (60 per arm; NCT02130466). The triple therapy arm had significantly higher rates of grade 3 to 5 treatment related adverse events (58% vs. 27%) and premature discontinuation due to TRAEs was 40% in the triple therapy arm compared with 20% for the dabrafenib/trametinib arm. The mean PFS was 16.0 months in the triple therapy group compared with 10.3 months in the dabrafenib/trametinib cohort, which was nonsignificant due to failure to meet one of the parameters for significance (hazard ratio < 0.66) and the median response duration was 18.7 months in the triple therapy group compared with 12.5 months for the dabrafenib/trametinib group.

The IMPemBra trial is a phase-II study comparing pembrolizumab monotherapy to pembrolizumab plus intermittent short-term targeted treatment with dabrafenib and trametinib for 1, 2, or 6 weeks to evaluate safety and tolerability (NCT02625337). Preliminary results have demonstrated increased overall response rates in the short-term BRAF/MEK cohorts compared with pembrolizumab monotherapy (objective response rate [ORR] at 18 weeks was 57% in the pembrolizumab monotherapy group, 71% in the cohort receiving dabrafenib and trametinib × 1 week, and 83% in the cohort receiving dabrafenib/trametinib × 2 weeks).

The ongoing COMBI-I trial is a phase-III study evaluating dabrafenib and trametinib with and without the PD-1 inhibitor spartalizumab (NCT02967692). The COMBI-I study is comprised of three distinct groups: a safety run-in, biomarker analysis with collection of tumor samples for immunohistochemistry, and a randomized double blind placebo-controlled phase to assess efficacy and safety of the dabrafenib and trametinib with and without spartalizumab. Preliminary results reported in 2018 described grade 3/4 adverse events occurring in 22% of patients but none led to treatment discontinuation. Significant increases in intratumoral CD8+ lymphocyte infiltration were observed after 2 to 3 weeks of therapy in eight out of nine patients, and the results of the PDL-1 expression and peripheral blood analysis will be reported at a later date. All seven patients evaluated at week 12 demonstrated an unconfirmed partial response, with no patients experiencing disease progression.

A phase-II trial of dabrafenib, trametinib, and the PD-1 inhibitor nivolumab is ongoing in patients with unresectable stage III and metastatic stage IV BRAF-mutant melanomas (NCT02910700). Preliminary results have been reported in 14 patients thus far, with 3 patients (21%) requiring drug discontinuation due to severe adverse events (one case of grade 3 immune-mediated hepatitis and two cases of immune-mediated nephritis). Eleven patients have been assessed for response thus far, with 10 patients (91%) showing a partial response and 1 patient experiencing disease progression.

A triple combination of the PDL-1 inhibitor atezolizumab, vemurafenib, and cobimetanib has been assessed in a recent phase Iib open-label study (NCT01656442). Enrolled patients had a 28-day lead-in phase with cobimetanib + vemurafenib followed by addition of atezolizumab. The confirmed ORR in 39 patients was 71.8%. The median response duration was 17.4 months, with ongoing response in 39.3% of patients after 29.9 months of follow-up. Toxicity of the triple combination was reported with 66% of patients on triple therapy having grade 3/4 TRAEs including elevations in liver transaminases, hypophosphatemia, and hyponatremia. In addition, a phase-III study (NEO-VC) of atezolizumab, vemurafenib, and cobimetanib is currently enrolling (NCT02303951).

In summary, combination therapy trials with BRAF/MEK and immunotherapy suggest potential synergistic effects with increased intratumoral CD8+ lymphocytes but long-term data on OS, PFS, and durability of responses achieved are not yet available. In addition, combinations of immunotherapy and targeted therapy may increase toxicity of treatment and optimal combinations of therapeutic agents, as well as dosing schedules are unknown at the present time, but hopefully optimal treatment strategies may become more evident as results begin to emerge from the ongoing phase-II and phase-III combination trials.

**Sequencing of Targeted Therapy and Immunotherapy**

As discussed above, combination studies of targeted therapies with anti-CTLA-4 or anti PD-1/PDL-1 agents may provide increased efficacy but increased toxicity of these combination regimens are a limiting factor. As such, utilizing the targeted therapies and immunotherapies in sequence as opposed to in combination is an area of active investigation, with the goal of potentially harnessing some of the benefits of combination therapy while minimizing toxicity.

There are currently two active clinical trials investigating the optimal sequencing of targeted therapy and immunotherapy agents. DREAM-SEQ (NCT02224781) is a phase-III trial in which patients are randomized to receive either ipilimumab + nivolumab or dabrafenib + trametinib, then cross over to the other treatment arm at disease progression.
The SECOMBIT (NCT02631447) study is a phase-II trial composed of the following three cohorts: encorafenib/binimetanib followed by ipilimumab/nivolumab (arm A), ipilimumab/nivolumab followed by encorafenib/binimetanib (arm B), and a “sandwich” arm treated first with encorafenib/binimetanib × 8 weeks, ipilimumab/nivolumab until disease progression followed by repeat encorafenib/binimetanib.

While data on optimal therapeutic sequencing from randomized controlled trials are pending, several previous retrospective studies have compared the outcomes of sequenced therapy with BRAF/MEK inhibition before or after immunotherapy. A multicenter retrospective study evaluated 274 patients with BRAF-mutant metastatic melanoma and compared outcomes between those who received first-line immunotherapy (high-dose interleukin-2, ipilimumab, nivolumab, or adoptive T-cell therapy) followed by targeted treatment (with trametinib monotherapy, vemurafenib monotherapy, or combined dabrafenib/trametinib) versus the reverse order.28 No significant difference in response to targeted therapy was observed whether it was first or second-line; however, for ipilimumab a decreased response was observed in patients receiving ipilimumab after targeted therapy.29 Likewise, in a retrospective analysis of a 93-patient cohort from the ipilimumab expanded access program, superior outcomes were observed in patients who were treated with front-line ipilimumab followed by single-agent vemurafenib or dabrafenib (median OS, 14.5 months) compared with patients initially treated with BRAF inhibition followed by ipilimumab (median OS, 9.9 months).29 A more recent retrospective study in 114 patients compared the ORR, OS, and PFS in patients treated with either anti-PD-1 agents or BRAF inhibitors first.30 It was noted that patients who progressed on PD-1 inhibitors had worse outcomes after transitioning to subsequent BRAF inhibitors compared with patients who had not received anti-PD-1 agents (median OS, 10.6 vs. 40.3 months; median PFS, 5.0 vs. 7.4 months). A similar phenomenon was observed in patients who started anti-PD-1 after progressing on BRAF inhibitor therapy, with poorer outcomes compared with patients who had not been treated with prior BRAF inhibitors (median OS, 8.2 vs 27.6 months; median PFS, 2.8 vs 10.6 months). The conclusion was that either front-line BRAF inhibitors or anti-PD-1 agents may be effective, regardless of treatment sequence, but there may be a “shared responder” phenotype between BRAF inhibitors and PD-1 agents with a poor response to one modality predicting a less than optimal response to the other.30

**Intratumoral Immunotherapy**

Involving direct injection of agents to promote tumor cell lysis, the goal of intratumoral immunotherapy is to promote both local and systemic antitumor immune responses while minimizing systemic toxicities.31 Talmogene laherparepvec (T-VEC) is a genetically modified herpes-simplex type 1 virus that was the first oncolytic virus approved for unresectable (stage IIIIB, IIIC, or IV) melanoma in 2015. T-VEC was engineered and a gene allowing replication in healthy cells (infected cell protein 34.5, ICP34.5) was removed, and granulocyte colony-stimulating factor (G-CSF) was added to stimulate the local immune response (recruitment of dendritic cells and presentation of tumor antigens to cytotoxic T-cells) upon tumor cell lysis to promote a systemic antitumor immune response.

Currently there are multiple trials examining T-VEC in combination with systemic anti-PD-1 agents, as well as investigating additional novel oncolytic viral candidates (CAVATEK and HF clone 10 [HF-10]), both as monotherapy, as well as in combination with immune checkpoint inhibitors for advanced and metastatic melanoma. In addition, there are multiple nonviral oncolytic agents in clinical trials including PV-10 (rose Bengal), SD-101 (toll-like receptor [TLR]-9 agonist), tilsotomod (TLR-9 agonist), and CMP-001 (TLR 7/8 agonist) which are reviewed briefly below.

**Oncolytic Viral Therapies**

**T-VEC in Combination with Systemic Immunotherapy**

T-VEC is currently being studied with both systemic ipilimumab, as well as pembrolizumab for unresectable and metastatic melanoma. A recent phase-II trial compared T-VEC plus ipilimumab to ipilimumab monotherapy in unresectable stage IIIB-IV melanoma (NCT01740297).32 The ORR was 39% in the combination arm compared to 18% for ipilimumab monotherapy, and responses of visceral lesions that had not been injected were seen in 52% of the combination arm compared with 23% of the ipilimumab monotherapy group. Grade 3 and higher adverse events were observed more frequently in the combination arm than for ipilimumab alone (45 vs. 35%) but overall the combination was well tolerated. T-VEC has also been evaluated in combination with pembrolizumab in a phase-Ib trial in which patients received local intratumor T-VEC injection (4 × 10^6 plaque forming units/mL) at week 1 and began pembrolizumab at week 3 coinciding with the second T-VEC injection.33 Biopsies were taken of injected tumors at baseline and at week 3 prior to the second T-VEC injection and before pembrolizumab commenced. The overall response rate was 62% (with 33% of patients having a complete response), and immunohistochemical analysis of tumors demonstrated increased CD8+ lymphocyte infiltration, as well as elevated PDL-1, and interferon (IFN)-γ expression after the initial T-VEC injection in patients who responded to combination therapy, suggesting that T-VEC may alter the tumor microenvironment to improve the efficacy of PD-1 inhibition.33 A phase-III trial of T-VEC and pembrolizumab is currently underway (NCT02263508).

**Coxsackievirus A21**

Coxsackievirus A21 (CAVATEK; Merck & Co.) is an unaltered coxsackie virus that preferentially infects cells that express increased levels of intercellular adhesion molecules (ICAMs) on their cell surface.34 In the phase-II open-label CAVATEK in melanoma (CALM) study (NCT01227551), 57 patients with stage IIIIC-IV melanoma were treated with intratumoral injection of CAVATEK on days 1, 3, 5, and 8 followed by a fifth injection 2 weeks later (day 22) and additional injections every 3 weeks (up to a maximum of 10 injections or confirmed disease progression). At 6 months, the ORR was 28% and no grade 3 or 4 adverse events were reported.35

---

This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited.
CAVATEK was studied in combination with ipilimumab in the phase-Ib study titled melanoma intertumoral CAVATEK and ipilimumab (MITCI; NCT02307149). The 2017 interim results report in 18 evaluable patients showed an overall response rate of 50%, and notably the response rate was higher in patients who had not been previously treated with a checkpoint inhibitor in the past (60%) compared with 38% in patients who had been previously treated with checkpoint inhibitors. However, responses were seen in patients who had developed progressive disease on previous checkpoint inhibitor therapy. In addition, CAVATEK is currently in phase-I trials in combination with pembrolizumab (NCT02307149) and results have not yet been reported.

**HF-10 (spontaneously mutated HSV-1)**

HF-10 (Takara Bio Inc.) is a herpes simplex type 1 (HSV-1) virus containing spontaneous mutations (not genetically engineered) that is spontaneously mutated and acts as a potent oncolytic agent. A phase-II trial in combination with ipilimumab has been completed in 44 patients with stage IIIB-IV melanoma (NCT02272855). The overall response rate at 24 weeks was 41%, with complete responses occurring in 16% of patients. At 24 weeks, 42.9% of responses had been maintained without progression. HF-10 is also being evaluated in a phase-II trial with nivolumab for unresectable stage IIIB-IV melanoma (NCT03259425).

**Nonviral Oncolytics**

**PV-10 (Rose Bengal Disodium)**

PV-10 (Provectus Biopharmaceuticals Inc.) is an injectable form of rose Bengal disodium (a xanthene dye) that accumulates in lysosomes after intratumoral injection leading to tumor lysis, and it has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for investigation in melanoma, as well as hepato cellular carcinoma. A phase-II study of PV-10 was recently completed in 80 patients with refractory metastatic melanoma (NCT005211053). The overall response rate was 51%, with a complete response being observed in 26% of patients. The main side effects were injection site tenderness and itching, and no grade 4 or 5 adverse events were observed. Intraleposureal PV-10 is also being evaluated in a phase Ib/II study in combination with pembrolizumab (NCT02557321), as well as a phase-III study, comparing intraleposureal PV-10, intraleposureal T-VEC, and systemic chemotherapy with dacarbazine or temozolomide in BRAF-wildtype melanoma who have failed at least one checkpoint inhibitor or are not candidates for checkpoint inhibitor therapy (NCT02288897).

**Toll-Like Receptor Agonists**

An important component of immunity, TLRs are transmembrane receptors expressed on a variety of leukocytes including dendritic cells, macrophages, NK cells, T-cells, and B-cells in addition to epithelial and endothelial cells that are involved in recognition of highly conserved antigens (such as those derived from bacteria, fungi, and viruses) and initiating the innate and adaptive immune responses. TLR agonists have shown potential utility in cancer treatment, by triggering T-cell responses that can lead to antitumor effects. Several TLR agonists have been studied in melanoma, including SD-101 (a TLR-9 agonist), tilsotolimod (also known as IMO-2125, a TLR-9 agonist), and NKTR-262 (a TLR 7/8 agonist). SD-101 (Dynavax Technologies) has been evaluated in a phase-Ib trial in conjunction with pembrolizumab for unresectable and metastatic melanoma (NCT02521870). Patients naïve to previous PD-1/PDL-1 therapy had a significantly better overall response rate than those who had previously had treatment with another PD-1/PDL-1 agent (ORR, 88 vs. 15%). In addition, immunohistochemical analysis of tumors was performed and an increase in CD8+ T cells, NK cells, dendritic cells, and B-cells was observed in both the PD-1 naïve and previously treated cohorts. Tilsotolimod IMO-2125 (Idera Pharmaceuticals) has been evaluated in combination with ipilimumab in a phase I/II study in patients with PD-1 refractory metastatic melanoma, and demonstrated an overall response rate of 38% (NCT02644967). In addition, tilsotolimod is also being evaluated in combination with ipilimumab for metastatic PD-1 refractory melanoma in the phase III ILLUMINATE-301 study (NCT03445533). Finally, NKTR-262 is a TLR 7/8 agonist that is currently being evaluated in the phase I/II REVEAL trial in advanced melanoma, MCC, colorectal cancer, urothelial carcinoma, and sarcoma in combination with NKTR-214 (a systemic CD-122 agonist) with or without nivolumab (NCT03435640).

**Merkel Cell Carcinoma**

Similarly to melanoma, the systemic treatment of MCC has changed dramatically with the development of anti-PD-1/PDL-1 immunotherapies. Avelumab and pembrolizumab are currently approved for metastatic MCC, and current trials are evaluating pembrolizumab, nivolumab, and ipilimumab (in combination with nivolumab) for the treatment of unresectable and metastatic MCC. There are also trials of multiple “next-generation” checkpoint inhibitors targeting the PD-1/PDL-1 axis including antibodies to T-cell immunoglobulin and mucin containing domain 3 (TIM-3), lymphocyte-activation gene-3 (LAG-3), and T cell immunoreceptor with Ig and immunoreceptor tyrosine-based inhibition motif (ITIM) domains (TIGIT). T-VEC (alone and in combination with nivolumab or radiation therapy) is also being evaluated in MCC, as are several TLR agonists either alone or combined with other immunotherapies. Finally, other immune-mediated treatment mechanisms including adoptive T-cell transfer, cell therapy with innate immune cells, and costimulatory T-cell agonists are in the early phases of trials for MCC.

**Pembrolizumab**

The phase II KEYNOTE-017 trial (NCT02267603) evaluated the use of pembrolizumab monotherapy in patients with stage III/IV MCC who had not previously had systemic therapy for their disease. Results reported in 2018 from 49 patients demonstrated an overall response rate of 56% (32% partial and 24% complete responses) with a median follow-up of 14.9 months. Based on these results, the FDA granted pembrolizumab approval for recurrent or metastatic MCC in 2018, and phase-III trials are currently ongoing to
assess pembrolizumab as first-line therapy in advanced MCC (NCT03783078).

Nivolumab
The PD-1 inhibitor nivolumab is currently in phase I/II trials as monotherapy for advanced MCC (CheckMate 358, NCT02488759), and demonstrated an overall response rate of 64%, as well as PFS of 75% at 6 months. In addition, the ongoing CheckMate 358 study is also investigating nivolumab in combination for metastatic MCC (phase II), as well as neoadjuvant therapy in resectable disease and in combination with daratumumab (anti-CD38 antibody, phase I) for unresectable or metastatic disease. There are several additional trials of nivolumab in the recruiting phase for MCC, including phase II in combination with ipilimumab and stereotactic radiation for metastatic MCC (NCT03071406), a phase-I/II trial of nivolumab or ipilimumab compared with placebo following resection of MCC (ADMEC-O, NCT03271372), as well as nivolumab + radiation therapy versus nivolumab, and ipilimumab following resection of MCC (NCT03798639).

‘Next-Generation’ Checkpoint Inhibitors
In addition to the inhibitory effect that PD-1/PDL-1 interaction has on the immune response, the tumor microenvironment contains several other inhibitory factors expressed by T-cells including LAG-3 and TIGIT. LAG-3 expression may be increased in activated CD8+ and CD4+ T-cells in the setting of chronic infections or malignancy, functioning analogous to PD-1 and suppressing the immune response. A monoclonal antibody to LAG-3 (INCAGNN02385) is currently being investigated in a phase-I study of advanced tumors including MCC (NCT03538028), and in one of the arms of the CheckMate 358 study evaluating a combination of nivolumab and relatamib (anti-LAG-3 antibody). TIM-3 TIM-3 is expressed by CD8+ T-cells within the tumor microenvironment and has been shown to promote T-cell exhaustion, representing a potential target for immunotherapeutic agents based on restoration of cytotoxicity following TIM-3 blockade in vitro. A monoclonal antibody against TIM-3 (INCAGN02390) is currently in phase-I trials for advanced tumors including MCC (NCT03652077). TIGIT TIGIT is a coinhibitory receptor expressed on T-cells and NK cells, and binding to its ligand (CD155) results in dampening of immune response in a manner analogous to PD-1. An anti-TIGIT antibody (AB154) is currently in phase-I/II trials both alone and in combination with a novel anti-PD1 antibody (AB154) in advanced tumors including MCC (NCT03628677).

T-VEC T-VEC is currently in phase-I trials for locally advanced MCC (NCT03458117), as well as phase-II studies in combination with radiation therapy for unresectable stages III/IV MCC (NCT02819843), as well as nivolumab (NCT02978625).

Toll-Like Receptor Agonists
Intratumoral injection of TLRs is currently being investigated as adjuvant agents along with checkpoint inhibitors in MCC. AST-008 is a TLR-9 agonist in phase-I/II trials in combination with pembrolizumab (NCT0364785). Another phase-I/II study is evaluating NKTR262 (A TLR 7/8 agonist) in combination with nivolumab and systemic NKTR214 (a CD122 agonist) in locally advanced and metastatic MCC (NCT03435640). Finally, polyICLC (polysinosinic-polycytidylic acid with polylysine and carbboxymethylcellulose, a TLR-3 agonist) is being investigated in phase-I/II trials in combination with durvalumab (anti-PDL-1 antibody) and tremilumimab (anti-CTLA-4 antibody; NCT02643303).

Adaptive T-Cell Immunotherapy
Adaptive T-cell immunotherapy involves the extraction of T-cells followed by subsequent selection and expansion of T-cells against a specific antigen, followed by reinfusion into the patient, and is being investigated as an adjuvant agent in the treatment of MCC using T-cells specific to the Merkel’s cell polyomavirus (MCPyV). A phase-I/II trial is evaluating adaptive T-cell therapy plus interferon versus avelumab and radiation therapy in MCPyV-positive unresectable MCC (NCT02584829), and another phase-I/II trial of MCPyV-specific autologous T-cells in combination with avelumab and radiation therapy is slated to begin recruiting (NCT03747484).

T-Cell Costimulation
T-cell activation involves binding of the TCR to a major histocompatibility complex (MHC) on the antigen presenting cell (APC) in addition to a second signal provided by interaction of costimulatory molecules on the T-cell and APC, and agonists for these costimulatory molecules are an additional adjuvant therapy in development for multiple cancers. CD27, OX40, 4 to 1 BB, and glucocorticoid-induced tumor necrosis factor (TNF) receptor-related protein (GTR) are all members of the TNF receptor superfamily and represent costimulatory ligands currently under investigation. A phase-I trial is investigating INCAGN01949 (an anti-OX40 agonistic antibody) in combination with nivolumab, ipilimumab, or both in the treatment of unresectable stage III/IV MCC (NCT03241173). INCAGN01876 is an anti-GTR agonistic antibody currently in two phase-I/II trials for MCC; in combination with nivolumab, ipilimumab, or both (NCT03126110) and in combination with pembrolizumab and epacadostat (inhibitor of indoleamine 2,3 dioxygenase 1 [IDO-1], which acts to suppress effector T-cell function; NCT03277352). In addition, ABBV-368 (an OX40 agonist) is under investigation in combination with ABBV-181 (an anti-PD-1 antibody) in a phase-I trial (NCT03071757).

Innate Immune Cell Therapy
Increased NK cells within the Merkel’s cell tumor microenvironment has been shown to be associated with better...
prognosis in MCPyV-associated tumors, and infusions of activated NK-92 (aNK) cells are being studied both alone and in combination with other agents in MCC. Infusions of Neukoplast (QUILT-3.009 NK cell line) are currently being evaluated in a phase-I single-arm open trial for unresectable stage III-IV MCC (NCT02465957).

**Cutaneous Squamous Cell Carcinoma**

Prior to the development of immune checkpoint inhibitors, treatment options for unresectable or metastatic cSCC and systemic treatments were limited to traditional chemotherapy (mainly with platinum-based agents, 5-fluorouracil derivatives, doxorubicin, bleomycin, and taxanes) and agents targeting the epidermal growth factor receptor (EGFR) such as cetuximab, erlotinib, and gefitinib. In 2018, cemiplimab became the first anti-PD-1 agent approved for metastatic and unresectable cSCC. Currently, there are clinical trials investigating cemiplimab as neoadjuvant therapy (either intratumoral or systemic) for recurrent cSCC prior to surgery, as well as an adjuvant agent after surgery, and radiation therapy in high-risk cSCC. In addition, there are multiple clinical trials of other anti-PD-1 agents for first-line treatment of unresectable or metastatic cSCC including pembrolizumab, nivolumab, avelumab, and cosibelimab (CK-301) which is an investigational anti-PDL-1 monoclonal antibody.

**Cemiplimab**

The approval of cemiplimab in 2018 for metastatic or unresectable cSCC was based on results from a phase-II study, demonstrating a 47% overall response rate and a response duration exceeding 6 months in 57% of patients who responded to cemiplimab (NCT02760498). In addition, cemiplimab was overall well-tolerated with the most common adverse events being diarrhea, fatigue, and nausea, and 7% of patients needed to discontinue cemiplimab due to a TRAE. Systemic cemiplimab is being evaluated as neoadjuvant therapy prior to surgical resection in stage II-IV cSCC (NCT04154943). Neoadjuvant intralesional cemiplimab is currently being studied in a phase-I trial for recurrent cSCC prior to surgical resection (NCT03889912). In addition, cemiplimab is being evaluated as adjuvant treatment after surgery and radiation for high-risk cSCC compared with placebo (NCT03969004).

**Other Anti-PD-1/PDL-1 Agents (Pembrolizumab, Nivolumab, Avelumab, and Cosibelimab (CK-301))**

Pembrolizumab and nivolumab were both approved in 2017 for the first-line treatment of unresectable or metastatic head and neck SCC; however, neither the phase-III study of nivolumab (Checkmate 041) nor the phase-Ib trial of pembrolizumab (KEYNOTE-012) evaluated any patients with cSCC. However, case series of both pembrolizumab and nivolumab have shown promising results in cSCC not amenable to surgical resection and both drugs are currently being evaluated in multiple clinical trials.

Pembrolizumab monotherapy is currently being evaluated as first-line treatment for advanced cSCC in four phase-II studies including the KEYNOTE-629 trial (NCT03284424), the CARSKIN trial (NCT02883556) and two additional trials in unresectable or metastatic cSCC (NCT02964559 and NCT02721732). Pembrolizumab is also being studied in combination with an intratumoral TLR-9 agonist (AST-008) in a phase-Ib/II trial for advanced cSCC (NCT03684785), as well as an adjuvant agent compared with placebo, following resection of locally advanced cSCC (KEYNOTE-630, NCT03833167). In addition, a phase-I trial of pembrolizumab and the MG1-MAGEA3 vaccine (a genetically modified form of the Maraba virus which acts as an oncolytic, coupled with the melanoma antigen family A3 [MAGE-3] antigen that is overexpressed in many tumor types including cSCC) is slated to begin recruiting (NCT03773744).

First-line nivolumab is currently being studied in two phase-II trials in locally advanced and metastatic cSCC (NCT03834233 and NCT04204837). Nivolumab is also being evaluated for unresectable and metastatic cSCC in kidney transplant patients in a phase-I trial (NCT03816332) given in conjunction with tacrolimus and prednisone, and patients who have progressive disease on nivolumab will be treated with combination nivolumab and ipilimumab.

There are currently two phase-II studies evaluating the anti-PDL-1 antibody avelumab in unresectable and metastatic cSCC: with and without the anti-EGFR antibody cetuximab (NCT03944941) and in combination with radical radiotherapy (NCT03737721). Cosibelimab (CK-301) is an investigational anti-PDL-1 monoclonal antibody, and is currently being evaluated in a phase-I trial in multiple types of advanced and metastatic cancers including cSCC, MCC, urothelial carcinoma, and both small-cell and non–small-cell lung adenocarcinoma (NCT03212404).

**Basal Cell Carcinoma**

While the vast majority of BCC tumors can be treated primarily with surgery and have an excellent prognosis, approximately 1% of patients develop advanced disease, defined as either locally advanced BCC (laBCC) or metastatic BCC (mBCC). Though the incidence of mBCC is extremely rare (0.0028–0.5%), it is associated with a median survival of approximately 8 months when nodal metastases are present. Approximately 85% of BCCs have mutations in the hedgehog signaling cascade, a pathway critical for cell proliferation and differentiation in embryogenesis, and the treatment of advanced and metastatic BCC has been revolutionized by the introduction of targeted agents inhibiting this pathway. Vismodegib is an inhibitor of the SMO receptor involved in the hedgehog pathway and was approved for advanced BCC in 2012. The approval of vismodegib was based on ERIVANCE, a multicenter, single-arm, two-phase-2 trial that assessed the efficacy and safety of vismodegib in patients with laBCC. In this study, 104 patients with laBCC and mBCC were treated with vismodegib 150 mg daily. At 39 months, investigator-assessed ORR was 60.3% in the laBCC group and 48.5% in the mBCC group. Median
duration of response was 26.2 months in laBCC and 14.8 months in mBCC, demonstrating the durability of response of this treatment option.\textsuperscript{67} Sonidegib is another orally dosed SMO inhibitor that is structurally distinct from vismodegib, and was approved in 2015 for locally advanced BCC. In the double-blind phase-2 BOLT trial, patients with laBCC or mBCC were randomized to either 200 or 800 mg of sonidegib daily. No additional efficacy was found between the two doses and in the 200-mg group, the ORR performed by central review was 56.1% for laBCC and 7.7% for mBCC at 30-month follow-up, with the 200-mg group also exhibiting a better safety profile.\textsuperscript{68}

To date, there are no head-to-head randomized controlled trials comparing vismodegib to sonidegib. In a meta-analysis of 1,102 patients, vismodegib and sonidegib demonstrated a similar overall response rate (RR) for laBCC (69 vs. 57%, respectively), whereas the complete RR differed drastically (31 vs. 3%, respectively). For metastatic disease, the overall RR of vismodegib was 2.7-fold higher than that of sonidegib (39 vs. 15%, respectively).\textsuperscript{69} However, there is a need for future head-to-head clinical trials to further compare the efficacy and safety profiles of these two agents.

Current areas of research in BCC include the use of SMO inhibitors as neoadjuvant agents prior to surgical resection of locally advanced BCC, topical SMO inhibitors (patidagib) for prevention and treatment of BCCs in the setting of BCC nevus syndrome (BCCNS) resulting from Patched-1 mutations, as well as to treat and prevent high-frequency BCCs in patients who do not have BCCNS, investigation of novel SMO inhibitors, as well as alternative targets for inhibition within the hedgehog pathway.

**Novel Smoothened Inhibitors**

Taladegib is an investigational oral SMO inhibitor that recently completed a phase dose-finding I clinical trial for advanced BCC (NCT01226485). Data from the phase-I study reported an overall response rate of 46.8% (in both patients who had previous hedgehog pathway inhibitors as well as hedgehog-naïve patients) with an acceptable safety profile.\textsuperscript{80} Phase-II trials are planned at doses below the maximum tolerated dose (MTD) of 400 mg daily that was identified in the phase-I study.

**Neoadjuvant Smoothened Inhibitors**

Neoadjuvant SMO inhibitors for laBCC have been investigated, specifically for BCCs at high risk for functional or aesthetic compromise with surgery in an effort to decrease the size of the defect required for tumor clearance. Current evidence for their use in the neoadjuvant setting is not well established, based primarily on open-label studies and case series. In an open-label study in 15 patients, vismodegib 150 mg daily was used for 3 to 6 months in the neoadjuvant setting, with a reduction of surgical defect size by 27% (95% confidence interval [CI]: −45.7 to −7.9%, \(p = 0.006\)). Four patients were not able to continue vismodegib longer than 3 months due to side effects, and 1 patient out of 11 evaluable patients had recurrence after a mean follow-up of 11.5 months.\textsuperscript{71} However, it is important to note that systemic SMO inhibitors do not always reduce tumor volume in a concentric fashion from the periphery, and may result in a tumor that effectively has “skip” lesions and reduce the accuracy of microscopically controlled excision methods such as Mohs’ surgery. Larger randomized placebo-controlled studies will be required to investigate the efficacy of neoadjuvant SMO inhibitors for advanced BCC.

**Topical Smoothened Inhibitors**

With more than one quarter of patients discontinuing treatment due to side effects, the use of topical SMO inhibitors is currently being explored. In a double-blind, vehicle-controlled, intraindividual study, 8 nevoid BCC patients with 27 BCCs were randomized to twice daily treatment of either 0.75% sonidegib cream (\(n = 13\)) or vehicle (\(n = 14\)). In the topical sonidegib group, three lesions demonstrated a complete response, and none had a partial response (PR); only one PR was noted in the placebo group.\textsuperscript{72} Topical patidagib is currently being studied for its ability to decrease BCC disease burden in the setting of BCCNS (phase III, NCT03703310) as well as in non-BCCNS high-frequency BCCs (phase II, NCT04155190).

**Alternative Targets in the Hedgehog Pathway**

In addition to side effects, resistance to SMO inhibitors raises a major concern, as approximately 5 to 10% of patients demonstrate resistance with eventual lack of response and progression of disease.\textsuperscript{65} The use of additional therapies directed at alternative downstream targets of the hedgehog signaling pathway have been considered for cases of resistance. Iraconazole, an FDA-approved antifungal, inhibits the hedgehog pathway by blocking SMO migration and has been shown to inhibit GLI expression in cells with vismodegib-resistant mutations. A clinical trial investigating the use of oral SUBA-itraconazole (SUBA-Cap) for BCCNS is currently in phase II (NCT02354261). Topical itraconazole is also in a phase-I study for non-BCCNS patients with BCC (NCT02735356). Additionally, direct inhibition of GLI transcription factors, terminal effectors in the hedgehog pathway, may also be a promising target in the treatment of laBCCs. Arsenic trioxide (ATO) is a chemotherapeutic agent that directly binds GLI1 and GLI2, preventing the accumulation of GLI in the primary cilium, an essential step in downstream hedgehog signaling.\textsuperscript{73} While combination therapies targeting more than one component of the hedgehog pathway may be more effective in combating resistance, future clinical studies are necessary for further confirmation.

**Immunotherapy (PD-1 Inhibitors)**

Pembrolizumab is currently in phase-II clinical trials for advanced BCC in combination with vismodegib (NCT02690948). Phase-I results were recently reported in which 16 patients were assigned to either pembrolizumab monotherapy versus pembrolizumab with oral vismodegib. Although not randomized, the authors concluded that the overall response rate of the pembrolizumab–vismodegib combination group was not subjectively superior compared with the pembrolizumab monotherapy group but merits further
investigation in larger randomized controlled trials.\textsuperscript{74} Cepilimumab monotherapy is currently in phase-II trials for in patients with BCC that had either progressed on or been intolerant prior hedgehog inhibitor therapy (NCT03132636) and results have not yet been published.\textsuperscript{75} However, a case report in one patient with metastatic BCC resistant to hedgehog inhibitors had a partial response with cepilimumab, and PFS was 32 weeks.\textsuperscript{76} Nivolumab has not been studied in clinical trials but has shown a partial response in a case report of one patient with metastatic BCC refractory to hedgehog inhibitors and a PFS time of 116 weeks.\textsuperscript{77}

**Conclusion**

The development of immunotherapeutic agents targeting the PD-1/PDL-1 axis has dramatically altered the treatment of and improved survival outcomes of many cancers that previously had limited therapeutic options in advanced stages, including melanoma, MCC, and cSCC. Numerous other treatments have emerged for melanoma, including the development of targeted agents against the BRAF/MEK pathway, as well intratumoral oncolytic agents, which are being investigated both alone and in combination with immunotherapy. Trials exploring various combinations and administration sequences of approved targeted therapies and immune-based treatments are underway in melanoma in an effort to help improve efficacy while minimizing toxicity. In addition, the treatment of advanced and metastatic BCC has been significantly improved by the development of targeted inhibitors of the hedgehog signaling pathway, and future directions include investigation of PD-1 inhibitors as a means to augment response and potentially treat BCCs that are resistant to hedgehog inhibitors. With multiple late-stage clinical trials underway, the next several years will provide valuable data on safety, efficacy, and durability of responses achieved by these recently approved targeted and immune-based therapies, as well as hopefully provide insight into the optimal treatment combinations, and regimens for advanced melanoma and non-melanoma skin cancers.

**Conflict of Interest**

J.A.C. reports grants from Regeneron, outside the submitted work. M.L.S. reports and coinvestigator on intralepithelial and treatment. M. all the other authors report no conflict of interest.

**References**

63 Tran DC, Colevas AD, Chang AL. Follow-up on programmed cell death 1 inhibitor for cutaneous squamous cell carcinoma. JAMA Dermatol 2017;153(01):92–94